A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer progressing after first-line chemo-immunotherapy (Combi-TED)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518224-74-01

Acronym

COMBI-TED

Enrollment

105

Registered

2025-02-07

Start date

2025-02-07

Completion date

Unknown

Last updated

2025-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic non-small-cell lung cancer

Brief summary

1-year Survival Rate

Detailed description

Overall Survival (OS) (1 and 2-year OS), Progression-free survival (PFS) (1 and 2-year PFS), Objective Response rate (ORR), Safety, Correlation of ORR, PFS and OS with tumor biomarkers

Interventions

DRUGNIVOLUMAB

DRUGTEDOPI

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1-year Survival Rate	—

Secondary

Measure	Time frame
Overall Survival (OS) (1 and 2-year OS), Progression-free survival (PFS) (1 and 2-year PFS), Objective Response rate (ORR), Safety, Correlation of ORR, PFS and OS with tumor biomarkers	—

Countries

France, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026